Article Text

other Versions

PDF
Extended report
Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)
  1. Joachim Sieper1,2,
  2. Joachim Listing2,
  3. Denis Poddubnyy1,
  4. In-Ho Song1,3,
  5. Kay-Geert Hermann4,
  6. Johanna Callhoff2,
  7. Uta Syrbe1,
  8. Jürgen Braun5,
  9. Martin Rudwaleit6
  1. 1Medical Department I, Rheumatology, Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
  2. 2German Rheumatology Research Center, Berlin, Germany
  3. 3Abbvie, Chicago, USA
  4. 4Department of Radiology, Charité University Medicine, Berlin, Germany
  5. 5Rheumazentrum Herne, Herne, Germany
  6. 6Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Bielefeld, Germany
  1. Correspondence to Professor Joachim Sieper, Medical Department I, Rheumatology, Charité University Medicine, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin 12200, Germany; Joachim.sieper{at}charite.de

Abstract

Background To date, only a single controlled trial provided evidence that non-steroidal anti-inflammatory drugs (NSAIDs) given continuously reduce radiographic progression compared with an on-demand therapy over 2 years in patients with ankylosing spondylitis (AS). In the current study, we tested whether such an effect of NSAIDs could be confirmed in another randomised trial.

Methods Patients with AS were randomised for treatment with either continuous (150 mg/day) or on-demand diclofenac for 2 years. Tumour necrosis factor-blocker treatment was not allowed during the entire study period. The primary outcome was the difference in radiographic progression in the spine as measured by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) scored by two readers blinded to treatment arm and time point.

Results 62 of 85 patients enrolled in the continuous arm and 60 of 82 enrolled in the on-demand arm completed the study. The mSASSS progression was numerically higher in the continuous group (1.28 (0.7 to 1.9) vs 0.79 (0.2 to 1.4)) (p=0.39). If only patients were analysed who were either C reactive protein positive or had syndesmophytes at baseline, there was again a higher radiographic progression in the continuous versus the on-demand group: 1.68 (0.7 to 2.6) vs 0.96 (0.0 to 1.9) and 2.11 (1.1 to 3.1) vs 0.95 (0.0 to 1.9), respectively. There was no difference between the two treatment groups regarding adverse events.

Conclusions In our study, continuous treatment with diclofenac over 2 years did not reduce radiographic progression compared with on-demand treatment in AS.

Trial registration numbers EudraCt-no 2007-007637-39; ClinicalTrials.gov NCT00715091.

  • Ankylosing Spondylitis
  • NSAIDs
  • Outcomes research

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles